title: Two-stage nanoparticle delivery of piperlongumine and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) anti-cancer therapy.
abstract: This study outlines a drug delivery mechanism that utilizes two independent vehicles, allowing for delivery of chemically and physically distinct agents. The mechanism was utilized to deliver a new anti-cancer combination therapy consisting of piperlongumine (PL) and TRAIL to treat PC3 prostate cancer and HCT116 colon cancer cells. PL, a small-molecule hydrophobic drug, was encapsulated in poly (lactic-co-glycolic acid) (PLGA) nanoparticles. TRAIL was chemically conjugated to the surface of liposomes. PL was first administered to sensitize cancer cells to the effects of TRAIL. PC3 and HCT116 cells had lower survival ratesin vitroafter receiving the dual nanoparticle therapy compared to each agent individually.In vivotesting involved a subcutaneous mouse xenograft model using NOD-SCID gamma mice and HCT116 cells. Two treatment cycles were administered over 48 hours. Higher apoptotic rates were observed for HCT116 tumor cells that received the dual nanoparticle therapy compared to individual stages of the nanoparticle therapy alone.
authors.affiliation: Meinig School of Biomedical Engineering, 205 Weill Hall, Cornell University, Ithaca, NY 14853, USA.
authors.forename: Charles C
authors.initials: CC
authors.lastname: Sharkey
authors.affiliation: Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
authors.forename: Jiahe
authors.initials: J
authors.lastname: Li
authors.affiliation: Meinig School of Biomedical Engineering, 205 Weill Hall, Cornell University, Ithaca, NY 14853, USA.
authors.forename: Sweta
authors.initials: S
authors.lastname: Roy
authors.affiliation: Meinig School of Biomedical Engineering, 205 Weill Hall, Cornell University, Ithaca, NY 14853, USA.
authors.forename: Qianhui
authors.initials: Q
authors.lastname: Wu
authors.affiliation: Meinig School of Biomedical Engineering, 205 Weill Hall, Cornell University, Ithaca, NY 14853, USA.
authors.forename: Michael R
authors.initials: MR
authors.lastname: King
keywords: Cancer; Nanomedicine; Nanoparticle; Piperlongumine; TRAIL; Therapy